Shakti Tripathi
Biotechnology
September 2022
The capacity to produce both humoral and cellular immune responses is a fundamental benefit of DNA vaccination. DNA vaccines are currently utilised in veterinary medicine, but due to their limited immunogenicity in early clinical research, they have not gained universal acceptability for use in humans. Recent clinical data, on the other hand, has re-established the utility of DNA vaccines, especially in priming high-level antigen-specific antibody responses. Advancements in DNA vaccine vector design, the addition of genetically modified cytokine adjuvants, and novel non-mechanical delivery methods have all been researched as ways to improve DNA vaccine efficacy. These techniques have demonstrated promise in mice and big animal models, leading in improved adaptive immune responses. Here, we look at recent developments in each of these domains that have the potential to improve the immunogenicity of DNA vaccines.
228- 239
© Airo Journals 2021
